glp 1 2026 The Medicare GLP-1 Bridge Begins July 1, 2026: What Our Patients Need to Know JoinSkinny GLP-1 Review 2026: Could

Drug repositioning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs

n = number of samples

What Triggered the Advisory The CDSCO advisory is prompted by a wave of multimedia obesity awareness campaigns launched by major pharmaceutical companies that, while stopping short of directly naming or promoting their drugs, were building public awareness around obesity as a disease and encouraging people to consult doctors, a strategy widely understood in the industry as a way to generate demand for GLP-1 therapies without technically violating India's prohibition on direct-to-consumer drug advertising

Second, considering evidence from clinical studies as informed by pre-clinical and mechanistic research, a putative benefit of GLP-1RAs on cognitive disorders (mediated by several neuroprotective mechanisms, especially anti-inflammatory effects

However, this same mechanism contributes to common side effects of GLP-1 medications such as nausea, bloating, and constipationespecially when doses are increased